Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows

Scientists may have discovered important step in the fight against antibiotic-resistant bacteria

Imagine falling seriously ill with an infection. Normally, we visit the doctor, are prescribed antibiotics, and after 7-10 days, we’re back on our feet. But today, it is no longer

Ex-Eye Bank Workers Say Pressure, Lax Oversight Led to Errors

William Lopez remembers clearly the day in June 2017 when he says he was asked to call the spouse of a college friend who had just died and ask for